WHAT IS CLAIMED IS:

1. Use of calcium lactate as an active ingredient in the manufacture of a medicament for treating cancer.

2. The use according to claim 1, wherein the calcium lactate is to be used in combination with radiation for treatment of cancer.

3. The use according to claim 2, wherein the radiation is to be irradiated to a cancer patient with an amount of radiation of 2 to 10 Gy per day and applied in combination with the calcium lactate.

4. The use according to claim 1, wherein the calcium lactate is to be used in combination with a known anticancer drug for treatment of cancer.

5. The use according to claim 4, wherein the anticancer drug includes one or more anticancer drugs selected from the group consisting of Imatinib, 5-FU (5-Florouracil), Irinotecan, Sunitinib, Oxaliplatin, Paclitaxel, Lapatinib, Trastuzumab (Herceptin), Gefitinib, Erlotinib, Methotrexate, Carboplatin, Docetaxel, Everolimus, Sorafenib, a carbonic anhydrase inhibitor, and a monocarboxylate transporter inhibitor.

6. The use according to any one of claims 1 to 5, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, stomach cancer, brain cancer, pancreatic cancer, thyroid cancer, skin cancer, bone cancer, lymphoma, uterine cancer, cervical cancer, kidney cancer, and melanoma.

7. Use of a pharmaceutical composition comprising calcium lactate as an active ingredient in the manufacture of a medicament for treating cancer, wherein the pharmaceutical composition further comprises pharmaceutically acceptable carriers, excipients, or diluents.

8. The use according to claim 7, wherein the pharmaceutical composition is formulated into liquid, powder, aerosol, injection, fluid transfusion (intravenous drip), patch, capsule, pill, tablet, depot, or suppository.

9. The use according to claim 8, wherein the pharmaceutical composition is formulated into liquid.

10. The use according to claim 8, wherein the pharmaceutical composition is formulated for injection or for fluid transfusion (intravenous drip).

11. The use according to claim 8, wherein the pharmaceutical composition is formulated as a transdermal patch.

12. The use according to any one of claims 7 to 11, wherein the pharmaceutical composition additionally comprises an anticancer drug.

13. The use according to claim 12, wherein the anticancer drug includes one or more anticancer drugs selected from the group consisting of Imatinib, 5-FU (5-Florouracil), Irinotecan, Sunitinib, Oxaliplatin, Paclitaxel, Lapatinib, Trastuzumab (Herceptin), Gefitinib, Erlotinib, Methotrexate, Carboplatin, Docetaxel, Everolimus, Sorafenib, a carbonic anhydrase inhibitor, and a monocarboxylate transporter inhibitor.

14. The use according to any one of claims 1 to 13, wherein the treating of cancer encompasses suppressing cancer metastasis.

15. The use according to claim 14, which suppresses the occurrence of one or more metastatic cancers selected from the group consisting of metastatic lung cancer, breast cancer, colorectal cancer, stomach cancer, brain cancer, pancreatic cancer, thyroid cancer, skin cancer, bone cancer, lymphoma, uterine cancer, cervical cancer, kidney cancer, and melanoma.